MERZ-THERAPEUTICS
11.8.2021 10:02:13 CEST | Business Wire | Press release
wMerz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and the Israeli start-up Vensica Therapeutics Ltd., a urology company, announced today that they have entered into a strategic license and collaboration agreement for the delivery of botulinum neurotoxin A (Xeomin®) ) to the bladder wall by using Vensica’s innovative ultrasound-assisted delivery catheter. By this, Merz Therapeutics becomes the exclusive toxin supplier of any needleless application for urological indications, such as overactive bladder, neurogenic bladder and interstitial cystitis and other urology indications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210811005052/en/
Stefan Brinkmann, CEO Merz Therapeutics: “This strategic, long-term partnership with the Israeli Start-up Vensica allows us to expand into the attractive market of overactive bladder. It perfectly reflects the potential and capabilities of our neurotoxin platform for the development of sizeable non-movement disorder indications, pursuing our promise to create better outcomes for more patients. We strongly believe in the innovative and less invasive treatment of bladder diseases using Vensica’s ultrasound-assisted delivery catheter and are therefore looking forward to bringing this new treatment option to the patients together with our partner Vensica.”
Vensica CEO, Avner Geva commented, “We are very excited about our strategic partnership with Merz. By licensing Merz’s Botulinum Toxin A, Xeomin® , we’ve achieved an important milestone in our journey to changing the lives of urological patients. We hope that together with Merz, we will be able to provide, needle-less and minimal invasive procedures to over 85 million patients around the world, enabling them to benefit from a minimal discomfort, anesthesia-free, outpatient experience. The partnership with Merz, which includes not only exclusive licensing of Xeomin® , but also development support, enables us to accelerate our clinical trials and regulatory process. We are thrilled Merz realized the potential and need and chose to invest in innovative medical technologies that can benefit patients worldwide.”
“The collaboration with Vensica is a great example for our Merz Corporate Venture Capital Initiative,” states Jörg Bergler, COO Merz Group. “Here, we are investing globally in companies who are pursuing innovative, breakthrough science. As an experienced partner, we are not only granting Vensica access to our toxin but also offer know-how and experience for the development and preparation of the regulatory approval process in an advisory capacity."
The long-term partnership includes Merz’s intention to participate and invest in Vensica. Under the terms of the agreement, Merz already received, in addition to royalties, equity shares from Vensica with the option for further investment in the upcoming years and will be represented with a seat in the Board of Directors. Vensica will be responsible for the pre-clinical and clinical development of the needleless device and will prepare and file the marketing approval application. Upon the marketing approval, Merz will be responsible for the manufacturing and supply of Xeomin® (incobotulinumtoxinA) and Vensica will manage commercial activities worldwide, except of Japan.
Vensica’s proprietary ultrasound-assisted drug delivery system is an innovative minimally invasive solution to urology. The system enables needleless delivery of drugs to the bladder wall in a simple and quick procedure. The platform drives treatment from the surgical center to the private clinics, as it removes the need for a highly trained urologist, staff, and anesthesia. The unique delivery profile enables uniform delivery of the neurotoxin to greater area of the bladder wall, which may increase its efficacy, such as earlier onset and longer effect. The device is at clinical development stage by Vensica Therapeutics an Israeli based company.
Xeomin® is being distributed by Merz Pharmaceuticals GmbH in more than 70 countries to treat patients with upper and lower limb spasticity, cervical dystonia, blepharospasm or hypersalivation. Merz uses state-of-the-art technology in its dedicated facility in Dessau, Germany, meeting the highest international standards for biologic manufacturing. The highly purified neurotoxin, the only active ingredient in Xeomin® , is made by removing complexing proteins from botulinum toxin type A, which is produced by Clostridium botulinum, using purification technology developed by Merz Pharma GmbH & Co. KGaA. The lack of complexing proteins enables Xeomin® to reduce the production of neutralizing antibodies capable of lowering efficacy.
About Merz Therapeutics
Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that meet patient and customer needs.
About Vensica Therapeutics Ltd.
Vensica is a urology therapeutics company based out of Israel. The company is developing a unique platform for drug delivery for several urinary bladder indications, based on a proprietary ultrasound-assisted drug delivery system. The company was founded in 2015 by Avner Geva, (Yale, B.Sc, Technion, M.Sc) and is led and backed by medical and therapeutic’s leaders, including chairman M.D., Ph.D, Nissim Darvish, Lew Pell, Laborie and The Trendlines Group.
About Merz
Merz Group is a global, diversified company based in Frankfurt, Germany, with the three businesses Merz Aesthetics, Merz Therapeutics and Merz Consumer Care. The company is family-owned for over 112 years and is distinguished by its commitment to innovation, long-term perspective, and focus on profitable growth. In fiscal year 2019/20 (June 30), Merz generated revenue of EUR 981.5 million. The company employs 3,212 people in 28 countries worldwide. To learn more, please visit www.merz.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005052/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 22:00:00 CET | Press release
Bhatt to lead enterprise technology strategy, AI deployment, and cyber and information security in Executive Leadership Team role Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise work
Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 22:00:00 CET | Press release
Radiation-resilient Lattice Nexus FPGAs have operated as specified in TESAT optical communication terminals since 2025 Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platf
New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 18:00:00 CET | Press release
New Survey of More Than 4,000 Players Finds 78% Play More During the Holidays and 82.5% Would Watch a Rewarded Ad in Exchange for a Bonus Offer Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an aud
The Rock-It Company Opens New Regional Office in Nashville16.11.2026 17:00:00 CET | Press release
The expansion demonstrates The Rock-It Company’s dedication to the iconic live music market and opens a new centralized hub that connects live events and luxury goods in a fast-growing region. The Rock-It Company, a global leader in live events and luxury goods logistics, announced the opening of a new regional office in Nashville, Tennessee, reinforcing its presence in one of the world's most important live music and cultural markets. The Nashville office brings together the full Rock-It platform with dedicated offices for Rock-It Cargo, Rock-It Sports, CARS by Rock-It and DIETL by Rock-It, serving as a regional hub for the company's broader portfolio of specialty logistics offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116286387/en/ The Rock-It Company office in Nashville, Tennessee “Nashville has been a central part of our business for decades, and we see tremendous opportunity to continue building on that f
IQM Supports NVIDIA’s Work to Make Quantum Computers Schedulable in Slurm16.11.2026 17:00:00 CET | Press release
IQM quantum computers already run at leading supercomputing centers, including Oak Ridge National Laboratory (ORNL), VTT Technical Research Centre of Finland, the Leibniz Supercomputing Centre (LRZ) and CINECA, with users reaching them through Slurm. IQM supports NVIDIA’s investment in making quantum processors a schedulable resource in supercomputing centers by integrating IQM quantum computers with Slurm. IQM’s partner MQSC (Munich Quantum Software Company) has demonstrated the MQSC Orchestrator scheduling IQM systems through the new Slurm capability. IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced at SC26 in Chicago its support for NVIDIA’s investment in making quantum processing units (QPUs) a schedulable resource in the Slurm workload manager by integrating IQM quantum computers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116814640/en/ NVIDIA is making q
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
